Search company, investor...

Predict your next investment

Takeda Pharmaceutical company logo
Corporation
HEALTHCARE | Pharmaceuticals / Drugs
takeda.com

Investments

27

Portfolio Exits

15

Partners & Customers

10

Service Providers

1

About Takeda Pharmaceutical

Takeda Pharmaceutical (TYO: 4502) (NYSE: TAK) is a research-based, global pharmaceutical company.

Headquarters Location

2-1-1 Nihonbashihonmachi, Chuo-ku

Tokyo, 103-8668,

Japan

+81 (0)3 3278 2111

Want to inform investors similar to Takeda Pharmaceutical about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest Takeda Pharmaceutical News

S.Korea and Japan compete in gastroesophageal reflux drug market

Jan 27, 2023

S.Korea and Japan compete in gastroesophageal reflux drug market HK Inno.N and Daewoong Pharmaceutical are challenging the Tokyo-based Takeda Pharmaceutical, the global market leader By South Korea is battling Japan again, this time on the global market to treat gastroesophageal reflux disease (GERD). South Korea's pharmaceutical product maker HK Inno.N is expanding the number of licensing offices for its GERD drug K-Cab, and Daewoong Pharmaceutical is doing the same for its Fexuclu medicine to take on the global market leader Taekcab made by Takeda Pharmaceutical of Japan. HK Inno.N on Thursday said it recently signed a contract with Europharma, a Brazilian pharmaceutical corporation, to export K-Cab technology. The former will transfer manufacturing technology and know-how to the latter, and Europharma will oversees product development and sales in Brazil for 10 years. Releasing the value of an export contract for pharmaceutical technology is standard, but not for this deal. Europharma requested that such information remain confidential because doing so will help the company gain a competitive edge against Brazilian market leader Takecab. Through its technology transfer deal in Brazil, HK Inno.N has laid the foundation for supplying K-Cab throughout the Americas. The Brazilian market for peptic ulcer medicine in 2020 was worth 800 billion won ($651 million), sixth in the world and No. 1 in South America. HK Inno.N first launched K-Cab in China and the Philippines and seeks to export the drug to 100 countries by 2028. On the same day, Daewoong Pharmaceutical said it applied for approval of Fexuclu with the Food and Drug Authority of Saudi Arabia, the 11th country where the company has filed such an application under its goal to sell the drug in 20 countries by 2025. In 2021, the peptic ulcer medicine market in Saudi Arabia was worth 410 billion won, ranking 12th worldwide and No. 1 in the Middle East. Write to Ji-Hyun Lee at bluesky@hankyung.com 1 Min read 2 Min read

Takeda Pharmaceutical Investments

27 Investments

Takeda Pharmaceutical has made 27 investments. Their latest investment was in Cardurion Pharmaceuticals as part of their Series B on October 10, 2021.

CBI Logo

Takeda Pharmaceutical Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

10/28/2021

Series B

Cardurion Pharmaceuticals

$300M

No

6

6/30/2021

Convertible Note

Carmine Therapeutics

$5M

Yes

1

4/20/2021

Series A

Adaptate Biotherapeutics

$18M

Yes

2

4/1/2021

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

10/6/2020

Seed VC

Subscribe to see more

Subscribe to see more

10

Date

10/28/2021

6/30/2021

4/20/2021

4/1/2021

10/6/2020

Round

Series B

Convertible Note

Series A

Seed VC

Seed VC

Company

Cardurion Pharmaceuticals

Carmine Therapeutics

Adaptate Biotherapeutics

Subscribe to see more

Subscribe to see more

Amount

$300M

$5M

$18M

$99M

New?

No

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

6

1

2

10

10

Takeda Pharmaceutical Portfolio Exits

15 Portfolio Exits

Takeda Pharmaceutical has 15 portfolio exits. Their latest portfolio exit was HilleVax on April 29, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

4/29/2022

IPO

HilleVax

$99M

Public

5

1/31/2022

Divestiture

Takeda Pharmaceutical - Gastrointestinal Line

$99M

1

7/31/2021

Spinoff / Spinout

HilleVax

$99M

1

9/17/2020

IPO

Subscribe to see more

$99M

Subscribe to see more

10

9/16/2020

Divestiture

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/29/2022

1/31/2022

7/31/2021

9/17/2020

9/16/2020

Exit

IPO

Divestiture

Spinoff / Spinout

IPO

Divestiture

Companies

HilleVax
Takeda Pharmaceutical - Gastrointestinal Line
HilleVax

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

5

1

1

10

10

Takeda Pharmaceutical Acquisitions

22 Acquisitions

Takeda Pharmaceutical acquired 22 companies. Their latest acquisition was Nimbus Lakshmi on December 13, 2022.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

12/13/2022

$99M

Acquired

1

1/10/2022

Series A

$99M

$18M

Acquired

11

10/27/2021

Other

$99M

Acquired

4

3/9/2021

Series B

Subscribe to see more

$99M

$99M

Subscribe to see more

10

4/16/2020

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/13/2022

1/10/2022

10/27/2021

3/9/2021

4/16/2020

Investment Stage

Series A

Other

Series B

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$18M

$99M

Note

Acquired

Acquired

Acquired

Subscribe to see more

Subscribe to see more

Sources

1

11

4

10

10

Takeda Pharmaceutical Partners & Customers

10 Partners and customers

Takeda Pharmaceutical has 10 strategic partners and customers. Takeda Pharmaceutical recently partnered with Discovery Education on November 11, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

11/15/2022

Partner

United States

Takeda and Discovery Education Partner on New Initiative Focusing on Health Equity

CHARLOTTE , N.C. and BOSTON November 16 , 2022 / 3BL Media / - Takeda Center for Health Equity and Patient Affairs , a global biopharmaceutical leader , and Discovery Education , the worldwide edtech leader , today announced a new partnership focused on transformative health equity education .

2

10/26/2022

Partner

United States

(Taylor Glascock for KHN). $38,398 for a Single Shot of a Very Old Cancer Drug

The development of Lupron Depot as an intramuscular shot that suppressed testosterone for months at a time improved patient compliance and also enabled its maker , Abbott Laboratories , and its Japanese partner , Takeda , to extend their patents on the drug into the 2000s , said Dr. Gerald Weisberg , a former Abbott Laboratories scientist who has been critical of the company 's pricing policies .

1

10/20/2022

Licensor

Germany

Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharma to Develop First-in-Class Celiac Disease Therapy

`` The continued development of TAK-227 in partnership with Zedira and Dr. Falk Pharma has the potential to offer A meaningful benefit to patients with celiac disease who suffer from symptoms and ongoing intestinal injury despite maintaining A gluten-free diet , '' said Chinwe Ukomadu , M.D. , Ph.D. , head , Gastroenterology at Takeda Pharmaceutical Company Limited .

5

9/29/2022

Partner

Switzerland

Subscribe to see more

Subscribe to see more

10

9/22/2022

Vendor

Italy

Subscribe to see more

Subscribe to see more

10

Date

11/15/2022

10/26/2022

10/20/2022

9/29/2022

9/22/2022

Type

Partner

Partner

Licensor

Partner

Vendor

Business Partner

Country

United States

United States

Germany

Switzerland

Italy

News Snippet

Takeda and Discovery Education Partner on New Initiative Focusing on Health Equity

CHARLOTTE , N.C. and BOSTON November 16 , 2022 / 3BL Media / - Takeda Center for Health Equity and Patient Affairs , a global biopharmaceutical leader , and Discovery Education , the worldwide edtech leader , today announced a new partnership focused on transformative health equity education .

(Taylor Glascock for KHN). $38,398 for a Single Shot of a Very Old Cancer Drug

The development of Lupron Depot as an intramuscular shot that suppressed testosterone for months at a time improved patient compliance and also enabled its maker , Abbott Laboratories , and its Japanese partner , Takeda , to extend their patents on the drug into the 2000s , said Dr. Gerald Weisberg , a former Abbott Laboratories scientist who has been critical of the company 's pricing policies .

Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharma to Develop First-in-Class Celiac Disease Therapy

`` The continued development of TAK-227 in partnership with Zedira and Dr. Falk Pharma has the potential to offer A meaningful benefit to patients with celiac disease who suffer from symptoms and ongoing intestinal injury despite maintaining A gluten-free diet , '' said Chinwe Ukomadu , M.D. , Ph.D. , head , Gastroenterology at Takeda Pharmaceutical Company Limited .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

1

5

10

10

Takeda Pharmaceutical Service Providers

1 Service Provider

Takeda Pharmaceutical has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Acq - P2P

Investment Bank

Financial Advisor

Service Provider

Associated Rounds

Acq - P2P

Provider Type

Investment Bank

Service Type

Financial Advisor

Partnership data by VentureSource

Takeda Pharmaceutical Team

38 Team Members

Takeda Pharmaceutical has 38 team members, including current Chief Executive Officer, President, Yasuchika Hasegawa.

Name

Work History

Title

Status

Yasuchika Hasegawa

Chief Executive Officer, President

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Yasuchika Hasegawa

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Chief Executive Officer, President

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Compare Takeda Pharmaceutical to Competitors

Woebot Health Logo
Woebot Health

Woebot is an automated conversational agent (chatbot) who helps users monitor their mood and learn about themselves. Drawing from a therapeutic framework known as Cognitive Behavior Therapy, Woebot asks people how they're feeling and what is going on in their lives in the format of brief daily conversations. Woebot is powered by artificial intelligence.

Iona Mind Logo
Iona Mind

Iona Mind is a mental health app that helps users with anxiety and depression. The company's content is derived from evidence-based protocols and Cognitive Behavioural Therapy (CBT).

XRHealth Logo
XRHealth

XRHealth creates medical & wellness applications using XR technology. For instance, XRHealth delivers an enhanced experience and real-time data analytics, for use in clinics and at home, where users can analyze and quantify performance through a digital experience. It was founded in 2016 and is based in Brookline, Massachusetts.

Amelia Virtual Care Logo
Amelia Virtual Care

Amelia Virtual Care offers treatment for behavioral and mental health issues through virtual reality immersion therapy. Its solutions allows professionals to treat all kinds of mental disorders from common phobias to anxiety and depression disorders. It was formerly known as Psious. The company was founded in 2013 and is based in Girona Spain.

Meru Health Logo
Meru Health

Meru Health is an online medical clinic treating depression and burnout. Meru Health's treatment program combines psychological treatment modules, patient data, and a licensed therapist. Meru Health individualizes the program based on patients' personal information and needs. It was founded in 2015 and is based in San Mateo, California.

Learn to Live Logo
Learn to Live

Learn to Live helps sufferers of mental health problems who have been too uncomfortable to ask for help, have struggled to find available psychologists or therapists, grown tired of traditional self-help or just want to try something new. The company also caters to employers, managed behavioral health organizations, employee assistance programs, and universities seeking to expand their mental health offerings for employees/members/students while simultaneously reducing the cost to deliver these programs.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.